Product Details

• Joint Health Support: this joint supplement contains the combination of 1500 mg Glucosamine HCl (FCHG49) and 1200 mg Chondroitin Sulfate (TRH122) that work together to help inhibit certain enzymes that break down cartilage and help promote joint comfort and mobility
   
• Cartilage Support: cartilage in the joint is produced and maintained by its own specialized cells. The protective cartilage cushion and joint fluid work together like a shock absorber to allow for proper joint function
   
• Clinically Proven: supported by more published research than any leading joint supplement. The revolutionary formula of ingredients works together to promote joint comfort at the cellular level, helping to block certain enzymes that break down cartilage
   
• Scientifically Researched High-Quality Ingredients: developed by a pharmacist, Cosamin is made with the utmost care and integrity by the same family-owned, American company for over 30 years
   
• Backed by Science: Nutramax Laboratories Consumer Care supplements are formulated with high-quality ingredients and backed by more than 80 quality checks to ensure you are receiving a safe and effective product

When it comes to your joints, there’s comfort in knowing that Cosamin is proven by more research than any other leading joint supplement.* Cosamin DS is proven to be effective in U.S. published clinical studies on joint health.* The revolutionary formula of ingredients work together to promote joint comfort at the cellular level, helping to block certain enzymes that break down cartilage*. The combination of our Glucosamine HCl and Chondroitin Sulfate in our joint supplement has been shown in cell culture research to decrease levels of markers associated with cartilage breakdown and joint discomfort.

*These statements have not been evaluated by the food and drug administration. This product is not intended to diagnose, treat, cure, or prevent any disease
*Based on top 10 brands of data reported by Nielsen through its AOD Service for the Supplement Category for the 52-week period ending 12/31/2021 for the U.S. market.